193 related articles for article (PubMed ID: 26843012)
1. Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.
Khalifa J; Tensaouti F; Chaltiel L; Lotterie JA; Catalaa I; Sunyach MP; Ibarrola D; Noël G; Truc G; Walker P; Magné N; Charissoux M; Ken S; Peran P; Berry I; Moyal EC; Laprie A
Eur Radiol; 2016 Nov; 26(11):4194-4203. PubMed ID: 26843012
[TBL] [Abstract][Full Text] [Related]
2. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
Khalifa J; Tensaouti F; Lotterie JA; Catalaa I; Chaltiel L; Benouaich-Amiel A; Gomez-Roca C; Noël G; Truc G; Péran P; Berry I; Sunyach MP; Charissoux M; Johnson C; Cohen-Jonathan Moyal E; Laprie A
J Neurooncol; 2016 Oct; 130(1):181-192. PubMed ID: 27502603
[TBL] [Abstract][Full Text] [Related]
3. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
4. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
5. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
6. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Eur Radiol; 2018 Jun; 28(6):2628-2638. PubMed ID: 29374321
[TBL] [Abstract][Full Text] [Related]
8. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
[TBL] [Abstract][Full Text] [Related]
9. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
10. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
Zhang H; Liu N; Gao S; Hu X; Zhao W; Tao R; Chen Z; Zheng J; Sun X; Xu L; Li W; Yu J; Yuan S
J Nucl Med; 2016 Apr; 57(4):524-9. PubMed ID: 26514171
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
12. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging-based tumour perfusion parameters are biomarkers predicting response after radiation to brain metastases.
Jakubovic R; Sahgal A; Soliman H; Milwid R; Zhang L; Eilaghi A; Aviv RI
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):704-12. PubMed ID: 25023291
[TBL] [Abstract][Full Text] [Related]
15. Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation.
Chan RW; Chen H; Myrehaug S; Atenafu EG; Stanisz GJ; Stewart J; Maralani PJ; Chan AKM; Daghighi S; Ruschin M; Das S; Perry J; Czarnota GJ; Sahgal A; Lau AZ
J Neurooncol; 2021 Jan; 151(2):267-278. PubMed ID: 33196965
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
17. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
[TBL] [Abstract][Full Text] [Related]
19. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
[TBL] [Abstract][Full Text] [Related]
20. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling.
Huang J; Wang AM; Shetty A; Maitz AH; Yan D; Doyle D; Richey K; Park S; Pieper DR; Chen PY; Grills IS
Magn Reson Imaging; 2011 Sep; 29(7):993-1001. PubMed ID: 21571478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
